Related Experiment Videos
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study
Matthew N Meriggioli1, Julie Rowin, Judith G Richman
1Department of Neurological Sciences, Rush University and Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. matthew_m_meriggioli@rush.edu
Annals of the New York Academy of Sciences
|November 1, 2003
Abstract:
Mycophenolate mofetil (MM) is an immunosuppressive agent developed and originally used to prevent acute rejection of solid-organ transplantation. There have been preliminary reports of its successful use in the treatment of autoimmune myasthenia gravis (MG). We conducted a double-blind, placebo-controlled pilot trial of MM in the treatment of suboptimally controlled, stable MG. Results of this pilot study are promising and suggestive of greater improvement in the patients who received MM compared to placebo.